LGVN - Longeveron extends gains on surging volume after publication of Alzheimer's data

Clinical-stage biotech, Longeveron (NASDAQ:LGVN) has extended its gains in the pre-market Friday as Wall Street continues to cheer the publication of results from a Phase 1 trial for its Alzheimer’s disease candidate Lomecel-B. Currently, Longeveron (LGVN) has added 13% with the trading of 9.3 million shares compared to the 65-day average volume of ~3.1 million. The peer-reviewed data from the 33-patient trial published in the Journal of the Alzheimer’s Association propelled the company shares on Thursday more than doubling its market cap. Longeveron (LGVN) has already added ~105% over the past five days alone, compared to the mostly unchanged SPDR S&P Biotech ETF (XBI) as shown in this graph.

For further details see:

Longeveron extends gains on surging volume after publication of Alzheimer’s data